DaVita Inc. (DVA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

DaVita Inc. (DVA) Healthcare & Pipeline Overview

DaVita Inc. (DVA) is a major player in the kidney dialysis services industry, providing comprehensive care for patients with chronic kidney failure. With a large network of dialysis centers and a focus on integrated care, DaVita serves a substantial patient base both domestically and internationally, positioning it as a key service provider in the healthcare sector.

What Is the Investment Thesis for DVA?

DaVita Inc. presents a compelling investment case based on its established market position and the growing prevalence of chronic kidney disease. With a P/E ratio of 12.4 and a profit margin of 5.6%, the company demonstrates financial stability. Growth catalysts include the increasing global incidence of diabetes and hypertension, major risk factors for kidney disease, and expansion of integrated care models. The company's extensive network of dialysis centers and focus on comprehensive kidney care services position it to capitalize on the rising demand for dialysis services. However, potential risks include regulatory changes, reimbursement pressures, and competition from other dialysis service providers. DaVita's ability to navigate these challenges will be crucial for sustained growth and profitability.

Based on FMP financials and quantitative analysis

DVA Key Highlights

Market capitalization of $11.4B reflects DaVita's significant presence in the healthcare sector.

• P/E ratio of 12.4 indicates a reasonable valuation compared to earnings.
• Gross margin of 31.1% demonstrates the company's ability to manage its cost of services effectively.
• Profit margin of 5.6% shows the profitability of DaVita's operations after all expenses.
• DaVita operates 2,815 outpatient dialysis centers in the United States, serving approximately 203,100 patients as of December 31, 2021, highlighting its extensive reach.

Who Are DVA's Competitors?

DVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DVA's Key Strengths?

Large and established network of dialysis centers.

• Strong relationships with payers (Medicare, Medicaid, private insurance).
• Focus on integrated care and disease management.
• Experienced management team.

What Are DVA's Weaknesses?

High dependence on government reimbursement rates.

• Exposure to regulatory changes and compliance risks.
• Competition from other dialysis service providers.
• Geographic concentration in the United States.

What Could Drive DVA Stock Higher?

Increasing prevalence of diabetes and hypertension driving demand for dialysis services.

• Potential for expansion into new international markets.
• Continued growth in home-based dialysis services.
• Development and implementation of new integrated care programs.

What Are the Key Risks for DVA?

Financial-distress signal — its Altman Z-Score of 1.68 sits in the distress zone (elevated bankruptcy risk).

• Insider selling — insiders were net sellers of roughly $17.7M recently.
• Changes in government reimbursement policies impacting revenue.
• Increased competition from other dialysis providers.
• Rising operating costs (labor, supplies, utilities).
• Medical malpractice claims and litigation.
• Regulatory scrutiny and compliance challenges.

What Are the Growth Opportunities for DVA?

• Expansion of Integrated Care Models: DaVita has the opportunity to expand its integrated care models, which provide comprehensive kidney care services to patients. This approach can improve patient outcomes and reduce healthcare costs, making it attractive to payers and patients. The market for integrated care is growing, driven by the shift towards value-based care. By expanding its integrated care offerings, DaVita can attract more patients and increase its revenue. The timeline for this growth opportunity is ongoing, as DaVita continues to develop and implement new integrated care programs.
• Geographic Expansion: DaVita can expand its presence in international markets, particularly in developing countries where the prevalence of kidney disease is increasing. The global dialysis services market is expected to grow significantly in the coming years, driven by the rising incidence of diabetes and hypertension. By expanding its geographic footprint, DaVita can tap into new markets and diversify its revenue streams. This expansion could occur over the next 3-5 years, as DaVita identifies and enters new markets.
• Home-Based Dialysis: DaVita can further promote and expand its home-based dialysis services. Home dialysis offers patients greater convenience and flexibility, and it can also be more cost-effective than in-center dialysis. The market for home dialysis is growing, driven by technological advancements and increasing patient demand. By expanding its home dialysis offerings, DaVita can attract more patients and improve its profitability. This growth opportunity is ongoing, as DaVita continues to invest in and promote its home dialysis services.
• Strategic Acquisitions: DaVita can pursue strategic acquisitions to expand its network of dialysis centers and enhance its service offerings. The dialysis services market is fragmented, with many small and independent providers. By acquiring these providers, DaVita can consolidate its market position and gain access to new patients and markets. This strategy can be implemented over the next 1-3 years, as DaVita identifies and acquires suitable targets.
• Technological Innovation: DaVita can invest in technological innovation to improve the efficiency and effectiveness of its dialysis services. This includes developing new dialysis machines, software, and data analytics tools. Technological innovation can improve patient outcomes, reduce costs, and enhance the patient experience. By investing in technology, DaVita can differentiate itself from its competitors and attract more patients. This is an ongoing opportunity, as DaVita continuously seeks to improve its services through technological advancements.

What Are DVA's Competitive Advantages?

• Extensive network of dialysis centers creates a significant barrier to entry for new competitors.
• Established relationships with government programs and private insurance companies provide a stable revenue stream.
• Focus on integrated care and disease management differentiates DaVita from other dialysis service providers.
• Strong brand reputation and patient loyalty contribute to its competitive advantage.

What Does DVA Do?

DaVita Inc., incorporated in 1994 and headquartered in Denver, Colorado, is a leading provider of kidney dialysis services for patients suffering from chronic kidney failure. Originally known as DaVita HealthCare Partners Inc., the company changed its name in September 2016 to DaVita Inc. The company operates a network of kidney dialysis centers and provides related lab services in outpatient dialysis centers. DaVita's services include outpatient, hospital inpatient, and home-based hemodialysis. It also owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for End-Stage Renal Disease (ESRD) patients. Additionally, DaVita offers management and administrative services to outpatient dialysis centers. DaVita provides disease management services to approximately 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements. The company also offers vascular access services, clinical research programs, physician services, and comprehensive kidney care services. As of December 31, 2021, DaVita provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers, serving approximately 203,100 patients. Internationally, it operated 339 outpatient dialysis centers in 10 countries, serving approximately 39,900 patients. Furthermore, DaVita provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. DaVita's comprehensive approach to kidney care and its extensive network of facilities solidify its position as a key player in the healthcare industry.

What Products and Services Does DVA Offer?

• Operates a network of kidney dialysis centers.
• Provides outpatient hemodialysis services.
• Offers hospital inpatient dialysis services.
• Delivers home-based hemodialysis services.
• Owns clinical laboratories that provide routine laboratory tests for dialysis patients.
• Provides management and administrative services to outpatient dialysis centers.
• Offers disease management services to patients in integrated care arrangements.
• Provides vascular access services, clinical research programs, and physician services.

How Does DVA Make Money?

• Generates revenue primarily from providing dialysis services to patients with chronic kidney failure.
• Receives payments from government programs (Medicare, Medicaid), private insurance companies, and patients.
• Operates outpatient dialysis centers and provides related lab services.
• Offers integrated care arrangements and disease management services to improve patient outcomes and reduce costs.

What Industry Does DVA Operate In?

DaVita operates in the medical care facilities industry, which is experiencing steady growth due to the rising prevalence of chronic diseases, particularly kidney disease. The market is competitive, with key players including Universal Health Services, Inc. and The Ensign Group, Inc. The industry is also subject to stringent regulations and reimbursement policies, which can impact profitability. DaVita's extensive network and integrated care model position it well to capitalize on the growing demand for dialysis services, but it must navigate the challenges of regulatory compliance and competition to maintain its market position.

Who Are DVA's Key Customers?

• Patients with chronic kidney failure requiring dialysis services.
• Hospitals requiring acute inpatient dialysis services.
• Government programs (Medicare, Medicaid) that reimburse for dialysis services.
• Private insurance companies that cover dialysis services for their members.

DaVita Inc. Financial Trajectory

DaVita Inc. (DVA) reported $3.55B in revenue for Q2 2026, reflecting 4.1% growth compared to the prior quarter. The company recorded net income of $265.4M, with diluted EPS of $4.02. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, DVA averaged $2.84 in diluted EPS.

Company Profile

DaVita Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Denver, US. The company is led by CEO Javier J. Rodriguez. DVA has traded publicly since 1995.

How DaVita Inc. Is Valued

DaVita Inc. carries a market capitalization of $11.4B, placing it in the large-cap category. Relative to its peer group, DVA's quantitative score of 77/100 is roughly in line with the peer average of 74/100.

Return on equity for DaVita Inc. stands at 81.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.5%, showing how much profit it generates from its asset base. DVA trades at a trailing price-to-earnings ratio of 12.40, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

DaVita Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.68 places it in the distress zone, a signal of elevated financial risk.

DaVita Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.3% above estimates on average.

Wall Street analysts project DaVita Inc. revenue of about $14.08B for fiscal 2026, with EPS near $14.79. The estimate reflects 5 contributing analysts.

Over the past six months, DaVita Inc. insiders filed 15 SEC Form 4 transactions — 6 sales and 9 purchases. On net that is roughly 85K shares disposed (about $17.7M), a signal worth weighing alongside the fundamentals.

DVA Financials

DVA Latest News

DVA Analyst Consensus

DVA MoonshotScore

Latest DaVita Inc. Analysis

What Investors Ask About DaVita Inc. (DVA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources